IMPORTANCE: Severe obesity (body mass index [BMI] ≥35) is associated with a broad range of health risks. Bariatric surgery induces weight loss and short-term health improvements, but little is known about long-term outcomes of these operations. OBJECTIVE: To report 3-year change in weight and select health parameters after common bariatric surgical procedures. DESIGN AND SETTING: The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium is a multicenter observational cohort study at 10 US hospitals in 6 geographically diverse clinical centers. PARTICIPANTS AND EXPOSURE: Adults undergoing first-time bariatric surgical procedures as part of routine clinical care by participating surgeons were recruited between 2006 and 2009 and followed up until September 2012. Participants completed research assessments prior to surgery and 6 months, 12 months, and then annually after surgery. MAIN OUTCOMES AND MEASURES: Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB), we assessed percent weight change from baseline and the percentage of participants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma glucose values less than 126 mg/dL without pharmacologic therapy. Dyslipidemia and hypertension resolution at 3 years was also assessed. RESULTS: At baseline, participants (N = 2458) were 18 to 78 years old, 79% were women, median BMI was 45.9 (IQR, 41.7-51.5), and median weight was 129 kg (IQR, 115-147). For their first bariatric surgical procedure, 1738 participants underwent RYGB, 610 LAGB, and 110 other procedures. At baseline, 774 (33%) had diabetes, 1252 (63%) dyslipidemia, and 1601 (68%) hypertension. Three years after surgery, median actual weight loss for RYGB participants was 41 kg (IQR, 31-52), corresponding to a percentage of baseline weight lost of 31.5% (IQR, 24.6%-38.4%). For LAGB participants, actual weight loss was 20 kg (IQR, 10-29), corresponding to 15.9% (IQR, 7.9%-23.0%). The majority of weight loss was evident 1 year after surgery for both procedures. Five distinct weight change trajectory groups were identified for each procedure. Among participants who had diabetes at baseline, 216 RYGB participants (67.5%) and 28 LAGB participants (28.6%) experienced partial remission at 3 years. The incidence of diabetes was 0.9% after RYGB and 3.2% after LAGB. Dyslipidemia resolved in 237 RYGB participants (61.9%) and 39 LAGB participants (27.1%); remission of hypertension occurred in 269 RYGB participants (38.2%) and 43 LAGB participants (17.4%). CONCLUSIONS AND RELEVANCE: Among participants with severe obesity, there was substantial weight loss 3 years after bariatric surgery, with the majority experiencing maximum weight change during the first year. However, there was variability in the amount and trajectories of weight loss and in diabetes, blood pressure, and lipid outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00465829.
IMPORTANCE: Severe obesity (body mass index [BMI] ≥35) is associated with a broad range of health risks. Bariatric surgery induces weight loss and short-term health improvements, but little is known about long-term outcomes of these operations. OBJECTIVE: To report 3-year change in weight and select health parameters after common bariatric surgical procedures. DESIGN AND SETTING: The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium is a multicenter observational cohort study at 10 US hospitals in 6 geographically diverse clinical centers. PARTICIPANTS AND EXPOSURE: Adults undergoing first-time bariatric surgical procedures as part of routine clinical care by participating surgeons were recruited between 2006 and 2009 and followed up until September 2012. Participants completed research assessments prior to surgery and 6 months, 12 months, and then annually after surgery. MAIN OUTCOMES AND MEASURES: Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB), we assessed percent weight change from baseline and the percentage of participants with diabetes achieving hemoglobin A1c levels less than 6.5% or fasting plasma glucose values less than 126 mg/dL without pharmacologic therapy. Dyslipidemia and hypertension resolution at 3 years was also assessed. RESULTS: At baseline, participants (N = 2458) were 18 to 78 years old, 79% were women, median BMI was 45.9 (IQR, 41.7-51.5), and median weight was 129 kg (IQR, 115-147). For their first bariatric surgical procedure, 1738 participants underwent RYGB, 610 LAGB, and 110 other procedures. At baseline, 774 (33%) had diabetes, 1252 (63%) dyslipidemia, and 1601 (68%) hypertension. Three years after surgery, median actual weight loss for RYGB participants was 41 kg (IQR, 31-52), corresponding to a percentage of baseline weight lost of 31.5% (IQR, 24.6%-38.4%). For LAGB participants, actual weight loss was 20 kg (IQR, 10-29), corresponding to 15.9% (IQR, 7.9%-23.0%). The majority of weight loss was evident 1 year after surgery for both procedures. Five distinct weight change trajectory groups were identified for each procedure. Among participants who had diabetes at baseline, 216 RYGB participants (67.5%) and 28 LAGB participants (28.6%) experienced partial remission at 3 years. The incidence of diabetes was 0.9% after RYGB and 3.2% after LAGB. Dyslipidemia resolved in 237 RYGB participants (61.9%) and 39 LAGB participants (27.1%); remission of hypertension occurred in 269 RYGB participants (38.2%) and 43 LAGB participants (17.4%). CONCLUSIONS AND RELEVANCE: Among participants with severe obesity, there was substantial weight loss 3 years after bariatric surgery, with the majority experiencing maximum weight change during the first year. However, there was variability in the amount and trajectories of weight loss and in diabetes, blood pressure, and lipid outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00465829.
Authors: Steven H Belle; Paul D Berk; William H Chapman; Nicholas J Christian; Anita P Courcoulas; Greg F Dakin; David R Flum; Mary Horlick; Wendy C King; Carol A McCloskey; James E Mitchell; Emma J Patterson; John R Pender; Kristine J Steffen; Richard C Thirlby; Bruce M Wolfe; Susan Z Yanovski Journal: Surg Obes Relat Dis Date: 2013-03-07 Impact factor: 4.734
Authors: Philip R Schauer; Bartolome Burguera; Sayeed Ikramuddin; Dan Cottam; William Gourash; Giselle Hamad; George M Eid; Samer Mattar; Ramesh Ramanathan; Emma Barinas-Mitchel; R Harsha Rao; Lewis Kuller; David Kelley Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: L Y Herring; C Stevinson; P Carter; S J H Biddle; D Bowrey; C Sutton; M J Davies Journal: Int J Obes (Lond) Date: 2017-03-06 Impact factor: 5.095
Authors: Ricard Corcelles; Mena Boules; Dvir Froylich; Amani Hag; Christopher R Daigle; Ali Aminian; Stacy A Brethauer; Barto Burguera; Philip R Schauer Journal: Obes Surg Date: 2016-08 Impact factor: 4.129
Authors: Anita P Courcoulas; Wendy C King; Steven H Belle; Paul Berk; David R Flum; Luis Garcia; William Gourash; Mary Horlick; James E Mitchell; Alfons Pomp; Walter J Pories; Jonathan Q Purnell; Ashima Singh; Konstantinos Spaniolas; Richard Thirlby; Bruce M Wolfe; Susan Z Yanovski Journal: JAMA Surg Date: 2018-05-01 Impact factor: 14.766
Authors: Rafael Alfonso-Cristancho; Wendy C King; James E Mitchell; Ramesh Ramanathan; Sean D Sullivan; Steven H Belle; David R Flum Journal: JAMA Date: 2016-10-18 Impact factor: 56.272
Authors: Albert Goday Arno; Magí Farré; Jose Rodríguez-Morató; Jose M Ramon; Clara Pérez-Mañá; Esther Papaseit; Ester Civit; Klaus Langohr; Marcel Lí Carbó; David Benaiges Boix; Olga Castañer Nino; Juana Antonia Flores Le Roux; Manuel Pera; Luis Grande; Rafael de la Torre Journal: Obes Surg Date: 2017-12 Impact factor: 4.129
Authors: Lingtak-Neander Chan; Charlotte H Neilson; Elizabeth A Kirk; Tiana F Colovos; Diane R Javelli; Saurabh Khandelwal Journal: Obes Surg Date: 2015-12 Impact factor: 4.129
Authors: Matthew L Maciejewski; David E Arterburn; Lynn Van Scoyoc; Valerie A Smith; William S Yancy; Hollis J Weidenbacher; Edward H Livingston; Maren K Olsen Journal: JAMA Surg Date: 2016-11-01 Impact factor: 14.766